IQVIA entered an agreement with Argenx SE for the development of new indications for VYVGART (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult patients who have a specific antibody receptor. Terms of the agreement were not disclosed.
 

The collaboration will support clinical development, regulatory, commercial and real-world evidence strategy to accelerate the development of new indications for VYVGART.
 

IQVIA will leverage its scientific expertise, technology and analytics to support Argenx in accelerating the clinical development of VYVGART.